Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT90001 + Nivolumab in Advanced Hepatocellular Carcinoma
NCT05178043Phase 2Active, not recruiting
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Aug 2021
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ascrinvacumab in hepatocellular carcinoma (HCC), sponsored by Kintor Pharmaceutical Limited. Started Aug 2021; status: active, not recruiting.
02
Drugs
ascrinvacumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05178043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178043.